RESUMO
Cerebral infarction presents with neurological deficits caused by the death of neurons in a focal area of the brain. S100B is a biomarker that increases in brain damage. Neuroprotectives can reduce the brain sequels after neurological insult. The purpose of this study was to evaluate the neuroprotective effects of L-carnitine and Fat emulsion (Lipofundin®) alone and in combination in patients with ischemic stroke. In a prospective, RCT, and double-blind study 100 patients with MCA ischemic cerebrovascular accident who were admitted in the first 24 h of injury entered the study. The patients were randomly assigned into four groups of L-carnitine, fat emulsion, L-carnitine plus fat emulsion and control. Fat emulsion 10%, 500 mL, was infused over 6 to 12 h and 1 gr of L-carnitine (10 mL of solution) was administered orally to patients in addition to common therapies, according to the American Heart Association and American Stroke Association (AHA/ASA) guidelines. The patients in the control group received only the usual treatment according to stroke guidelines. Blood samples before the intervention, then after 24 h, 48 h, and 7 days later were taken and immunoenzymatic colorimetric method was used for quantitative determination of S100B concentration in the patients' serum. In the within group analysis, all of our treatment interventions (except control group) have decreased S100B levels statistically significant (P < 0.05). Moreover, changes in observed levels of S100B before and after intervention were different between the groups and the observed differences were statistically significant (P = 0.01). In the GEE model, it was found that S100B levels in the L-carnitine plus fat emulsion group decreased more than the control group and this decline has been statistically significant [P = 0.02, 20.47 (CI 95%: 6.25-34.41)], but in comparison of L-carnitine and fat emulsion group with control group, did not reached statistical significance (P > 0.05). Based on the results obtained from this study, it seems that L-carnitine with fat emulsion could lead to neuroprotective effects with a significant reduction in the S100B biomarker.
RESUMO
BACKGROUND: The main reason for the failure of endodontic therapy is the incomplete knowledge about the anatomical variation of root canals. One of the most important factors that leads to the failure of root canal treatment, is missed and untreated major root canals. OBJECTIVE: with respect to the complexity of mandibular incisors treatment and high prevalence of the second canal, and the possibility of the relationship between the crown size and the extra canal in these teeth, the aim of this study was to determine the relationship between crown size and root canal morphology in mandibular incisors with CBCT. METHODS: In this cross-sectional study, mandibular permanent incisors were randomly collected in Qazvin City, Iran, and were mounted in eight ternary groups on a plastic slot, using putty molding material. After preparation of Scot view, the samples were scanned by CBCT NewTom 5G. Afterward, the mesiodistal and buccolingual dimensions were measured by the software's measurement tool with a precision within tenths of a millimeter. In the next stage, a multi-planar option and 400% magnification tool of the software were utilized to study axial and cross sectional views of each tooth to determine canal type. Data were analyzed employing one-sample Kolmogorov-Smirnov, Levene, independent- samples t-test and Roc curve by SPSS version 20. RESULTS: The majority of mandibular incisors have a single canal (63.9% of them had type I canal system). In addition, 36.1% of the roots had two canals, among which, type III was the most common. The mean of maximum mesiodistal and buccolingual diameters in type III was significantly bigger than that in type I (p<0.05), but the means of crown size in the two canal types were not significantly different. CONCLUSION: Despite increase in mesiodistal and buccolingual dimension in two canal mandibular incisors with type III canal system, their crown sizes (M-D/F-L index) were not significantly different, in comparison to single canal incisors.
RESUMO
Cancer patients are more susceptible to adverse drug-drug interactions (DDIs) due to receiving multiple medications especially chemotherapy medications, hormonal agents and supportive care drugs. The aim of this study is to describe the prevalence of potential DDIs and to identify risk factors for these potential interactions in hospitalized cancer patients in a developing country. A cross-sectional study conducted by reviewing charts of 224 consecutive in hospitalized patients in hematology-oncology ward of a teaching hospital in Tehran, during a 12 month period from July 2009 to July 2010. "Drug Interaction Facts 2008, 2009: The Authority on Drug Interactions" was used for screening the potential drug-drug interactions. Potential interactions were classified by levels of severity and documentation. The median age of patients was 50 years, the length of hospital stay for patient was 5 days and the number of drugs per patient was 8 drugs. Two hundred and twenty-eight potential interactions were detected. Nearly 14% of the interactions were major and 60% were moderate. Approximately 9% and 10% potential interactions were graded as established and probable. In multivariate analysis, being older than 61 years old, suffering from hematologic cancer, source of cancer in different specific organs (esophagus, testis and cervices more than other sources), and number of ordered drugs for patients were independent predictors of having at least one potential DDI in hospital order. Suffering from hematologic cancer, source of cancer in different organs, length of hospital stay and number of ordered drugs for patients were independent predictors for number of interactions per patients. Having a DDI seems to be more likely to occur in patients older than 61 years old. Hematologic cancers, having more medications in physician's order, longer length of hospital stay, esophageal cancer, testicular cancer and cervical cancer have related to having a DDI and also having more number of interactions.
